The aging cardiovascular system: understanding it at the cellular and clinical levels

F Paneni, C Diaz Cañestro, P Libby, TF Lüscher… - Journal of the American …, 2017 - jacc.org
Cardiovascular disease (CVD) presents a great burden for elderly patients, their caregivers,
and health systems. Structural and functional alterations of vessels accumulate throughout …

Heart regeneration by endogenous stem cells and cardiomyocyte proliferation: controversy, fallacy, and progress

L He, NB Nguyen, R Ardehali, B Zhou - Circulation, 2020 - Am Heart Assoc
Ischemic heart disease is the leading cause of death worldwide. Myocardial infarction
results in an irreversible loss of cardiomyocytes with subsequent adverse remodeling and …

A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN …

R Bolli, RD Mitrani, JM Hare, CJ Pepine… - European journal of …, 2021 - Wiley Online Library
Aims CONCERT‐HF is an NHLBI‐sponsored, double‐blind, placebo‐controlled, Phase II
trial designed to determine whether treatment with autologous bone marrow‐derived …

An update on the progress of isolation, culture, storage, and clinical application of human bone marrow mesenchymal stem/stromal cells

DT Chu, TNT Phuong, NLB Tien, DK Tran… - International journal of …, 2020 - mdpi.com
Bone marrow mesenchymal stem/stromal cells (BMSCs), which are known as multipotent
cells, are widely used in the treatment of various diseases via their self-renewable …

Clinical studies of cell therapy in cardiovascular medicine: recent developments and future directions

MN Banerjee, R Bolli, JM Hare - Circulation research, 2018 - Am Heart Assoc
Given the rising prevalence of cardiovascular disease worldwide and the limited therapeutic
options for severe heart failure, novel technologies that harness the regenerative capacity of …

Transient secretion of VEGF protein from transplanted hiPSC-CMs enhances engraftment and improves rat heart function post MI

X Ai, B Yan, N Witman, Y Gong, L Yang, Y Tan… - Molecular Therapy, 2023 - cell.com
Cell-based therapies offer an exciting and novel treatment for heart repair following
myocardial infarction (MI). However, these therapies often suffer from poor cell viability and …

Translational cardiac stem cell therapy: advancing from first-generation to next-generation cell types

E Cambria, FS Pasqualini, P Wolint, J Günter… - NPJ Regenerative …, 2017 - nature.com
Acute myocardial infarction and chronic heart failure rank among the major causes of
morbidity and mortality worldwide. Except for heart transplantation, current therapy options …

Global position paper on cardiovascular regenerative medicine

F Fernández-Avilés, R Sanz-Ruiz… - European heart …, 2017 - academic.oup.com
Based on the increasingly understood regenerative capacity of the human heart and
vascular system, 1 cardiovascular regenerative medicine (CRM) encompasses all potential …

Therapies to prevent post-infarction remodelling: From repair to regeneration

P Contessotto, A Pandit - Biomaterials, 2021 - Elsevier
Myocardial infarction is the first cause of worldwide mortality, with an increasing incidence
also reported in develo** countries. Over the past decades, preclinical research and …

Mending a broken heart: current strategies and limitations of cell-based therapy

LC Liew, BX Ho, BS Soh - Stem Cell Research & Therapy, 2020 - Springer
The versatility of pluripotent stem cells, attributable to their unlimited self-renewal capacity
and plasticity, has sparked a considerable interest for potential application in regenerative …